Genetics

Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “In 2017, we demonstrated the clinical activity of our two lead product candidates that turn “cold” tumors “hot,” …

Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“In 2017, we demonstrated the clinical activity of our two lead product candidates that turn “cold” tumors “hot,” and enhanced our balance sheet,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design. “In 2018, our goal is to continue to create value and advance these novel therapies toward registration paths for patients with sarcoma and follicular lymphoma, while also setting the stage for potential expansion into multiple larger patient tumor populations.”

Click here to read the full press release.

MARKETS

Markets
TSX19254.560.00
TSXV619.760.00
DOW32197.590.00
S&P 5004023.610.00
NASD12032.420.00
ASX6823.20+15.90

COMMODITIES

Commodities
Gold1750.22+11.58
Silver19.71+0.57
Copper3.46+0.03
Palladium2071.50+50.50
Platinum891.00+3.00
Oil97.31+0.05
Heating Oil3.640.00
Natural Gas8.50-0.05

DOWNLOAD FREE REPORTS

×